In the evolving field of biochemical research, the term peptide 110 often appears in discussions surrounding mitochondrial dynamics and cellular integrity. For those of us who track advancements in synthetic biology and biomolecular studies, understanding the nuances between various compoun The DRP1 inhibitory peptide P110 provides ds—such as the P110 heptapeptide and other similarly named sequences—is essential for maintaining clarity in our research documentation.
Understanding the P110 Heptapeptide
The most frequently cited entity under this designation is a specific seven-amino acid peptide designed to interact with cellular machinery. Scientific literature consistently characterizes this molecule as a Drp1-specific inhibitor. By modulating the interaction between Drp1 and Fis1, this compound effectively influences mitochondrial fission processes.
From a research perspective, P110 is a seven-amino acid peptide that has garnered significant attention because P110 is neuroprotective. In laboratory models, this sequence effectively reduced DRP1 and p-DRP1 levels, which is a critical metric for investigators focusing on mitochondrial health. Furthermore, studies have shown that P110 is able to attenuate the deposition of beta-amyloid in SH-SY5Y cells, highlighting its potential utility in specialized cellular assays.
Research Applications and Mechanisms
When exploring the utility of this compound, it is important to note that P110 heptapeptide can be used for research on neurological and inflammatory diseases. The mechanism is highly targeted; by inhibiting mitochondrial fragmentation and the subsequent production of reactive oxygen species (ROS), it provides neuroprotection after subarachnoid hemorrhage.
My own observation of the data suggests that P110 is a Drp1-specific inhibitor that acts with high preci SERUM PK PARAMETERS FOR CIN-110 FIGURE 1 sion. Whether researchers are investigating P110-family mitochondrial fission-related peptides or evaluating how a specific peptide might be used to stabilize cellular environments, the results in models of neurodegeneration, ischemia, and sepsis remain a primary focus. Indeed, the neuroprotective properties of this sequence are often verified by its ability to reduce mitochondrial damage and organ injury in various experimental settings.
Distingui by S Hao·2025·Cited by 4—Treatment with the selective DRP1 inhibitor P110effectively reduced DRP1 and p-DRP1 levels, attenuated neuronal apoptosis and blood-brain Read more shing Between Related Entities
It is common for those new to the field to confuse different sequences that share similar nomenclature. For instance, peptide p110 is distinct from other laboratory tools:
* CP110 peptide: Unlike the mitochondrial-targeted P110, the CP110 peptide is used for b 3 days ago—The p110 peptide is widely described in the scientific literature as aseven-amino acid peptide—often referred to as the P110 heptapeptide—that Read more loc Syntaxin 1, also known as p35, is a small integral membrane protein that is abundantly expressed in neurons and neuroendocrine cells. It was initially Read more king the activity of CP110 antibody, serving a purely analytical purpose in Western Blotting or immunohistochemistry.
* CIN-110: This is an entirely different class of molecule. CIN-110 is a potent and highly selective peptide YY (PYY3-36) analog. I The DRP1 inhibitory peptide P110 provides t functions through different pathways, specifically design The authors showed thatP110 is able to attenuate the deposition of beta-amyloid in SH-SY5Y cellsby an increase of expression of APP and BACE1 mRNA and by a Read more ed to gradually increase then sustain drug exposures, and it is currently being studied for its metabolic impact, such as how it reduces diabetes risk and enhances heart health.
* C-Peptide: This is a naturally occurring 31-amino-acid polypeptide. A C-peptide test measures C-peptide in your blood or urine to determine how much insulin your body makes, which is vastly different from synthetic research peptides.
* ACTH (1-10), human: Another sequence often encountered in literature, though it lacks the specific mitochondrial-inhibitory functions of the Drp1-targeting heptapeptide.
Final Review Observations
For those involved in laboratory research, the distinction between a blocking agent—like the sequence that is used for blocking the activity of IPR1 antibody—and a functional modulator like P110 is paramount. As a user of these products, I find it crucia ta 110 peptide peptide l to emphasize that these compounds are strictly for experimental use.
Whether you are looking into the structural composition of a seven-amino acid peptide or analyzing the pharmacokinetic profiles of metabolic analogs, always ensure that your sourcing aligns with the specific catalog number and intended use case. The landscape of peptide research is vast, and maintaining a clear distinction between these entities ensures the integrity of your experimental outcomes.